Page 66 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology An update on SLE

6.6. Rituximab Conflict of interest

Rituximab, a B-cell-depleting antibody, is used in patients The authors declare that they have no competing interests.
who have not responded to standard treatments. While its
role remains uncertain, observational studies suggest it is Author contributions
effective for treating SLE and lupus nephritis. 84 Conceptualization: Abdurahman Alloghbi, Fahad S.
6.7. Investigational approaches Alshehri
Writing – original draft: All authors
The investigational approach involves cellular therapies Writing – review & editing: Fahad S. Alshehri
such as atacicept, anti-IL-6 receptor inhibitors, iberdomide,
low-dose IL-2, obinutuzumab, daratumumab, anti-CD40 Ethics approval and consent to participate
monoclonal antibody, litifilimab, and teclistamab. Details
on ongoing clinical trials for SLE treatments in the US are Not applicable.
available at www.clinicaltrials.gov. Consent for publication

7. Conclusion and future perspectives Not applicable.
SLE is a complex autoimmune disorder with significant Availability of data
global health implications. Its multifactorial etiology,
involving genetic, environmental, and hormonal factors, Not applicable.
leads to immune dysregulation and widespread organ
damage. Despite advancements in understanding its References
pathogenesis, early diagnosis and effective management 1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med.
remain critical for improving patient outcomes. Although 2011;365(22):2110-2121.
mortality rates have declined over the years, SLE continues doi: 10.1056/NEJMra1100359
to contribute to higher morbidity and mortality, particularly
due to complications such as lupus nephritis and CVD. In 2. Isenberg D, Ehrenstein M, Rahman A. Introduction to a
regions, such as Saudi Arabia, where healthcare disparities systemic lupus erythematosus - biomarkers meeting held at
University College London on 23 and 24 February 2007.
th
rd
and delayed diagnoses are common, SLE presents a Lupus. 2008;17(3):231.
substantial public health challenge.
doi: 10.1177/0961203307088257
The future of SLE management appears promising,
with ongoing research exploring novel therapies, including 3. Quirno N, Porrini A, Marino P, Iotti R. Causes of death in
cytokine inhibitors, cellular therapies, and personalized systemic lupus erythematosus. Prensa Med Argent. 1970.
medicine approaches. Advances in biomarker discovery and 57(22):1056-1059.
the integration of artificial intelligence in disease monitoring 4. Fei Y, Shi X, Gan F, et al. Death causes and pathogens analysis
have the potential to enhance early diagnosis and improve of systemic lupus erythematosus during the past 26 years.
treatment precision. In addition, addressing gaps in healthcare Clin Rheumatol. 2014;33(1):57-63.
access, particularly in underserved populations, will be doi: 10.1007/s10067-013-2383-3
crucial for improving global outcomes. Collaborative efforts 5. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD.
among researchers, clinicians, and policymakers are essential Manifestations of systemic lupus erythematosus. Maedica
for advancing SLE care, reducing its burden, and ultimately (Bucur). 2011;6(4):330-336.
enhancing the quality of life for patients worldwide.
6. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic
Acknowledgments opportunities in systemic lupus erythematosus: State of
the art and prospects for the new decade. Ann Rheum Dis.
We acknowledge King Faisal Medical City for Southern 2010;69(9):1603-1611.
Region (KFMCity), King Fahad Medical City, and doi: 10.1136/ard.2010.135186
King Khalid University for their support, and Palestine
Polytechnic University for their collaboration. The figure 7. Stoddard CJ, Kay PH, Simms JM, Kennedy A, Hughes P.
presented in this paper was created using the BioRender Acute abdominal complications of systemic lupus
software. erythematosus. Br J Surg. 1978;65(9):625-628.
doi: 10.1002/bjs.1800650911
Funding
8. Palmer DG. Systemic lupus erythematosus with cerebral
None. complications. N Z Med J. 1988;101(840):91.

Volume 9 Issue 3 (2025) 58 doi: 10.36922/EJMO025090042